NL-OMON46569已完成3 期
AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS - IMPALA-EX
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Savara ApS
- 入组人数
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Completer of the IMPALA trial
排除标准
- •1. Treatment with GM-CSF products other than molgramostim nebuliser solution within three months of Baseline.
- •2. Treatment with any IMP other than inhaled molgramostim within four weeks of Baseline.
- •3. History of allergic reactions to GM-CSF.
研究者
相似试验
进行中（未招募）
1 期
Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to assess continued treatment with molgramostim by inhalatioAutoimmune Pulmonary Alveolar Proteinosis (aPAP)MedDRA version: 20.0Level: LLTClassification code 10037316Term: Pulmonary alveolar proteinosisSystem Organ Class: 100000004855EUCTR2017-004078-32-DKSavara ApS90
进行中（未招募）
1 期
Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to assess continued treatment with molgramostim by inhalatioAutoimmune Pulmonary Alveolar Proteinosis (aPAP)MedDRA version: 20.0 Level: LLT Classification code 10037316 Term: Pulmonary alveolar proteinosis System Organ Class: 100000004855EUCTR2017-004078-32-GBSavara ApS90
进行中（未招募）
1 期
Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to assess continued treatment with molgramostim by inhalatioAutoimmune Pulmonary Alveolar Proteinosis (aPAP)MedDRA version: 20.0Level: LLTClassification code 10037316Term: Pulmonary alveolar proteinosisSystem Organ Class: 100000004855EUCTR2017-004078-32-ITSavara ApS90
进行中（未招募）
1 期
Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to assess continued treatment with molgramostim by inhalatioAutoimmune Pulmonary Alveolar Proteinosis (aPAP)MedDRA version: 20.0Level: LLTClassification code 10037316Term: Pulmonary alveolar proteinosisSystem Organ Class: 100000004855EUCTR2017-004078-32-FRSavara ApS90
进行中（未招募）
1 期
Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to assess continued treatment with molgramostim by inhalatioAutoimmune Pulmonary Alveolar Proteinosis (aPAP)MedDRA version: 20.0Level: LLTClassification code 10037316Term: Pulmonary alveolar proteinosisSystem Organ Class: 100000004855EUCTR2017-004078-32-DESavara ApS90